Literature DB >> 32004447

Bi-allelic Variants in RALGAPA1 Cause Profound Neurodevelopmental Disability, Muscular Hypotonia, Infantile Spasms, and Feeding Abnormalities.

Matias Wagner1, Yuliya Skorobogatko2, Ben Pode-Shakked3, Cynthia M Powell4, Bader Alhaddad5, Annette Seibt6, Ortal Barel7, Gali Heimer8, Chen Hoffmann9, Laurie A Demmer10, Yezmin Perilla-Young4, Marc Remke11, Dagmar Wieczorek12, Tharsini Navaratnarajah6, Peter Lichtner13, Dirk Klee14, Hanan E Shamseldin15, Fuad Al Mutairi16, Ertan Mayatepek6, Tim Strom5, Thomas Meitinger17, Fowzan S Alkuraya15, Yair Anikster3, Alan R Saltiel2, Felix Distelmaier18.   

Abstract

Ral (Ras-like) GTPases play an important role in the control of cell migration and have been implicated in Ras-mediated tumorigenicity. Recently, variants in RALA were also described as a cause of intellectual disability and developmental delay, indicating the relevance of this pathway to neuropediatric diseases. Here, we report the identification of bi-allelic variants in RALGAPA1 (encoding Ral GTPase activating protein catalytic alpha subunit 1) in four unrelated individuals with profound neurodevelopmental disability, muscular hypotonia, feeding abnormalities, recurrent fever episodes, and infantile spasms . Dysplasia of corpus callosum with focal thinning of the posterior part and characteristic facial features appeared to be unifying findings. RalGAPA1 was absent in the fibroblasts derived from two affected individuals suggesting a loss-of-function effect of the RALGAPA1 variants. Consequently, RalA activity was increased in these cell lines, which is in keeping with the idea that RalGAPA1 deficiency causes a constitutive activation of RalA. Additionally, levels of RalGAPB, a scaffolding subunit of the RalGAP complex, were dramatically reduced, indicating a dysfunctional RalGAP complex. Moreover, RalGAPA1 deficiency clearly increased cell-surface levels of lipid raft components in detached fibroblasts, which might indicate that anchorage-dependence of cell growth signaling is disturbed. Our findings indicate that the dysregulation of the RalA pathway has an important impact on neuronal function and brain development. In light of the partially overlapping phenotype between RALA- and RALGAPA1-associated diseases, it appears likely that dysregulation of the RalA signaling pathway leads to a distinct group of genetic syndromes that we suggest could be named RALopathies.
Copyright © 2020 American Society of Human Genetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  GARNL1; RalA signaling; TULIP1; West syndrome; epilepsy; muscular hypotonia; neurodevelopmental disorder

Mesh:

Substances:

Year:  2020        PMID: 32004447      PMCID: PMC7010976          DOI: 10.1016/j.ajhg.2020.01.002

Source DB:  PubMed          Journal:  Am J Hum Genet        ISSN: 0002-9297            Impact factor:   11.025


  26 in total

1.  The small GTPase RalA targets filamin to induce filopodia.

Authors:  Y Ohta; N Suzuki; S Nakamura; J H Hartwig; T P Stossel
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-02       Impact factor: 11.205

2.  RalA signaling pathway as a therapeutic target in hepatocellular carcinoma (HCC).

Authors:  Mohamad Ezzeldin; Emma Borrego-Diaz; Mohammad Taha; Tuba Esfandyari; Amanda L Wise; Warner Peng; Alex Rouyanian; Atabak Asvadi Kermani; Mina Soleimani; Elham Patrad; Kristina Lialyte; Kun Wang; Stephen Williamson; Bashar Abdulkarim; Mojtaba Olyaee; Faris Farassati
Journal:  Mol Oncol       Date:  2014-04-13       Impact factor: 6.603

3.  Downregulation of Ral GTPase-activating protein promotes tumor invasion and metastasis of bladder cancer.

Authors:  R Saito; R Shirakawa; H Nishiyama; T Kobayashi; M Kawato; T Kanno; K Nishizawa; Y Matsui; T Ohbayashi; M Horiguchi; T Nakamura; T Ikeda; K Yamane; E Nakayama; E Nakamura; Y Toda; T Kimura; T Kita; O Ogawa; H Horiuchi
Journal:  Oncogene       Date:  2012-03-26       Impact factor: 9.867

Review 4.  Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?

Authors:  Dominico Vigil; Jacqueline Cherfils; Kent L Rossman; Channing J Der
Journal:  Nat Rev Cancer       Date:  2010-11-24       Impact factor: 60.716

5.  Functions of cholera toxin B-subunit as a raft cross-linker.

Authors:  Charles A Day; Anne K Kenworthy
Journal:  Essays Biochem       Date:  2015       Impact factor: 8.000

6.  Cloning and characterization of GRIPE, a novel interacting partner of the transcription factor E12 in developing mouse forebrain.

Authors:  Julian Ik Tsen Heng; Seong-Seng Tan
Journal:  J Biol Chem       Date:  2002-08-27       Impact factor: 5.157

7.  Genetic deletion of RALA and RALB small GTPases reveals redundant functions in development and tumorigenesis.

Authors:  Pascal Peschard; Afshan McCarthy; Valérie Leblanc-Dominguez; Maggie Yeo; Sabrina Guichard; Gordon Stamp; Christopher J Marshall
Journal:  Curr Biol       Date:  2012-10-11       Impact factor: 10.834

8.  TULIP1 (RALGAPA1) haploinsufficiency with brain development delay.

Authors:  Keiko Shimojima; Yuta Komoike; Jun Tohyama; Sonoko Takahashi; Marco T Páez; Eiji Nakagawa; Yuichi Goto; Kousaku Ohno; Mayu Ohtsu; Hirokazu Oguni; Makiko Osawa; Toru Higashinakagawa; Toshiyuki Yamamoto
Journal:  Genomics       Date:  2009-09-03       Impact factor: 5.736

9.  Tuberous sclerosis tumor suppressor complex-like complexes act as GTPase-activating proteins for Ral GTPases.

Authors:  Ryutaro Shirakawa; Shuya Fukai; Mitsunori Kawato; Tomohito Higashi; Hirokazu Kondo; Tomoyuki Ikeda; Ei Nakayama; Katsuya Okawa; Osamu Nureki; Takeshi Kimura; Toru Kita; Hisanori Horiuchi
Journal:  J Biol Chem       Date:  2009-06-11       Impact factor: 5.157

10.  A comprehensive framework for prioritizing variants in exome sequencing studies of Mendelian diseases.

Authors:  Miao-Xin Li; Hong-Sheng Gui; Johnny S H Kwan; Su-Ying Bao; Pak C Sham
Journal:  Nucleic Acids Res       Date:  2012-01-12       Impact factor: 16.971

View more
  1 in total

1.  Dysregulation of RalA signaling through dual regulatory mechanisms exerts its oncogenic functions in hepatocellular carcinoma.

Authors:  Lu Tian; Luqing Zhao; Karen Man-Fong Sze; Charles Shing Kam; Vanessa Sheung-In Ming; Xia Wang; Vanilla Xin Zhang; Daniel Wai-Hung Ho; Tan-To Cheung; Lo-Kong Chan; Irene Oi-Lin Ng
Journal:  Hepatology       Date:  2021-12-17       Impact factor: 17.298

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.